Recently, a novel nanomedicine has been constructed that can activate CD4+ T cells and CD8+ T cells and polarize the M2 macrophages to M1 macrophages, which induced potent anti-tumor immunity and has good clinical application prospects (193). The gene discussed is CD4; the disease is neoplasm.